Comparative Analysis of Nine COVID-19 Convalescent Plasma Protocols Registered by Cochrane Central Register of Controlled Trials


Convalescent plasma
Neutralizing antibody
Passive antibody transfer

How to Cite

Cui, J., & Ke, Y. (2020). Comparative Analysis of Nine COVID-19 Convalescent Plasma Protocols Registered by Cochrane Central Register of Controlled Trials. Iranian Red Crescent Medical Journal, 22(8).



Context: Coronavirus disease 2019 (COVID-19) has progressed into a public health emergency of international concern. Passive immunotherapy has been successfully used for the treatment of infectious diseases since the 1890s. It is necessary and constructive to compare and analyze COVID-19 convalescent plasma (CCP) randomized controlled trials (RCTs) to help clinicians to have a potential option for COVID-19.

Evidence Acquisition: In this study, eight databases were searched on May 1, 2020, such as China National Knowledge Infrastructure, PubMed, and Cochrane Library, with the search fields of "Title Abstract Keyword" of "Convalescent plasma AND COVID-19" or " Convalescent plasma AND SARS-CoV-2". The outcome of interest was clinical RCTs for COVID-19.

Results: The search retrieved nine relevant CCP protocols for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). All nine trials were randomized, parallel assignment, interventional, clinical treatment studies with NCT04344535, NCT04345289, and NCT04323800 masking and the rest open-label. The estimated enrollment is within the range of 40-1,500 subjects, and five trials will be finished in 2020 as opposed to two in 2021 and two in 2022. Except for NCT04323800 on the prevention of COVID-19, other eight trials will test and verify the effectiveness and safety of CCP for the treatment of COVID-19.

The used dosage of CCP is within the range of 200-600 mL. NCT04344535, NCT04323800, and NCT04346446 use standard donor plasma in controlled groups in comparison to NCT04348656, NCT04342182, NCT04333251, and NCT04345523 without any positive drug in controlled groups. NCT04332835 adds hydroxychloroquine to both groups, and only NCT04345289 is a six-armed placebo-controlled trial.

Primary and secondary outcome measures are differently expressed in the nine trials. Nevertheless, they can be summarized as ㈠ changes in time, day, and number of a 7-point ordinal scale. There are ㈡ changes in SARS-CoV-2 ribonucleic acid (i.e., viral load), anti-SARS-CoV-2 antibody titers (i.e., immunoglobulin M and immunoglobulin G), C-reactive protein, lymphocyte count, lactate dehydrogenase, and interleukin 6 on a specified day or during a specific period.

Conclusion: The nine well-designed RCT trials will establish the efficacy of CCP for the treatment of SARS-CoV-2 from the perspective of evidence-based medicine.


Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 Patients. J Infect Dis. 2020;222(1):38-43. doi: 10.1093/infdis/jiaa228. [PubMed: 32348485].

Teixeira da Silva JA. Convalescent plasma: a possible treatment of COVID-19 in India. Med J Armed Forces India. 2020;
76(2):236-37. doi: 10.1016/j.mjafi.2020.04.006. [PubMed: 32296259].

Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-8.

Sullivan HC, Roback JD. Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic. Transfus Med Rev. 2020;In Press. doi: 10.1016/j.tmrv.2020.04.001. [PubMed: 32359788].

Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;
20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. [PubMed: 32113510].

Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256. doi: 10.1136/bmj.m1256. [PubMed: 32217555].

Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757-65. doi: 10.1172/JCI138745. [PubMed: 32254064].

Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020;In Press. doi: 10.1002/jmv.25961. [PubMed: 32356910].

Xie M, Chen Q. Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020;94:119-24. doi: 10.1016/j.
. [PubMed: 32247050].

Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020;92(5):479-90. doi: 10.1002/jmv.25707. [PubMed: 32052466].

NCT04344535. Convalescent plasma vs. standard plasma for COVID-19. Available at: URL: https://www.cochranelibrary.
; 2020.

NCT04323800. Efficacy and safety human coronavirus immune plasma (HCIP) vs. control (SARS-CoV-2 Non-immune Plasma) among adults exposed to COVID-19. Available at: URL:; 2020.

NCT04332835. Convalescent plasma for patients with COVID-19: a randomized, open label, parallel, controlled clinical
study. Available at: URL:
; 2020.

NCT04348656. Convalescent plasma for hospitalized adults with COVID-19 respiratory illness (CONCOR-1). Available
at: URL:
; 2020.

NCT04342182. convalescent plasma as therapy for Covid-19 severe SARS-CoV-2 disease (CONCOVID Study). Available
at: URL:; 2020.

NCT04346446. Efficacy of convalescent plasma therapy in severely sick COVID-19 patients. Available at: URL:; 2020.

NCT04345289. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. Available at: URL:; 2020.

NCT04333251. Study testing convalescent plasma vs best supportive care. Available at: URL: https://www.cochraneli
; 2020.

NCT04345523. Convalescent plasma therapy vs SOC for the treatment of COVID19 in hospitalized patients. Available
at: URL:
; 2020.

Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):
599-609. doi: 10.7326/0003-4819-145-8-200610170-00139. [PubMed: 16940336].

Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-56. doi: 10.1093/cid/ciq106. [PubMed: 21248066].

Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676-8. doi: 10.1111/j.1469-0691.2004.00956.x. [PubMed: 15214887].

Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A(H5N1) infection. N Engl J Med. 2007;
357(14):1450-1. doi: 10.1056/NEJMc070359. [PubMed: 17914053].

Dean CL, Hooper JW, Dye JM, Zak SE, Koepsell SA, Corash L, et al. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfusion. 2020;60(5):1024-31. doi: 10.1111/trf.
. [PubMed: 32129478].

Rubin R. Testing an old therapy against a new disease: convalescent plasma for COVID-19. JAMA. 2020;In Press. doi: 10.1001/jama.2020.7456. [PubMed: 32352484].

Dzik S. COVID-19 convalescent plasma: now is the time for better science. Transfus Med Rev. 2020;In Press. doi: 10.1016/j.tmrv.2020.04.002. [PubMed: 32359789]

Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, Chen JI, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 Novel Coronavirus (2019-nCoV): a systematic review. J Clin Med. 2020;9(3):623. doi: 10.3390/jcm9030623. [PubMed: 32110875].